Eager investors drove shares of Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) to a 52-week high of $13.09 Monday after the company reported phase II data on AVP-923 to treat agitation in patients with Alzheimer's disease (AD). Shares closed the day at $12.49 for a gain of $5.75, or 85.3 percent, on volume of more than 87 million – 40 times the company's daily average.